

**WHAT IS CLAIMED IS:**

1. An adenoviral vector that mediates increased gene delivery *in vivo* comprising:

5 a targeting component that targets said vector to specific target cells; and a tissue-specific promoter that drives the expression of a transgene carried by said vector in said target cells.

10

2. The adenoviral vector of claim 1, wherein said targeting component is selected from the group consisting of a targeting ligand incorporated into the fiber protein of said adenoviral vector by genetic mutation, a targeting ligand incorporated into a 15 capsid protein of said adenoviral vector by genetic mutation, and a bi-specific molecule that binds to the knob protein of said adenoviral vector and a molecule expressed on said target cells.

3. The adenoviral vector of claim 2, wherein said bi-specific molecule is a bi-specific antibody conjugate linking a Fab fragment of an anti-Ad5 knob antibody with an anti-angiotensin converting enzyme antibody.

5

4. The adenoviral vector of claim 3, wherein said anti-Ad5 knob antibody is 1D6.14 and said anti-angiotensin converting enzyme antibody is 9B9.

10

5. The adenoviral vector of claim 4, wherein said tissue-specific promoter is selected from the group consisting of vascular endothelial growth factor type 1 receptor promoter, ICAM-2 promoter, vonWillebrand factor promoter and vascular endothelial growth factor receptor promoter.

15  
20 6. The adenoviral vector of claim 5, wherein said target cells are pulmonary endothelial cells.

7. A method of gene delivery by adenoviral vector,  
comprising the step of:  
contacting target cells with an adenoviral vector  
5 comprising a targeting component that targets said vector to specific  
target cells and a tissue-specific promoter that drives the expression  
of a transgene carried by said vector in said target cells, wherein  
said adenoviral vector has increased targeting specificity to said  
target cells and results in reduced transgene expression in non-  
10 target cells.

8. The method of claim 7, wherein the targeting  
component of said adenoviral vector is selected from the group  
15 consisting of a targeting ligand incorporated into the fiber protein of  
said adenoviral vector by genetic mutation, a targeting ligand  
incorporated into a capsid protein of said adenoviral vector by  
genetic mutation, and a bi-specific molecule that binds to the knob  
protein of said adenoviral vector and a molecule expressed on said  
20 target cells.

9. The method of claim 8, wherein said bi-specific molecule is a bi-specific antibody conjugate linking a Fab fragment of an anti-Ad5 knob antibody with an anti-angiotensin converting enzyme antibody.

5

10. The method of claim 9, wherein said anti-Ad5 knob antibody is 1D6.14 and said anti-angiotensin converting enzyme antibody is 9B9.

10

11. The method of claim 10, wherein the tissue-specific promoter of said adenoviral vector is selected from the group consisting of vascular endothelial growth factor type 1 receptor promoter, ICAM-2 promoter, vonWillebrand factor promoter and 15 vascular endothelial growth factor receptor promoter.

12. The method of claim 11, wherein the target cells 20 are pulmonary endothelial cells.